eligibility criteria

Variables to be extracted

Primary and secondary endpoints

Data abstraction methodology

Statistical analysis plan

Ensure the protocol follows Pharma SOP checklist standards and is stored with version control.

Step 3: Obtain IRB/Ethics Committee Approval

Even though the study uses existing data, ethical oversight is often required. Consider:

• Whether informed consent is needed or a waiver is appropriate
• Ensuring data is de-identified or coded
• Maintaining patient confidentiality

Submit the study protocol, data handling plan, and privacy safeguards to an Institutional Review Board (IRB) or Ethics Committee as per local regulations and pharmaceutical compliance guidelines.

Step 4: Design the Data Abstraction Tool

A structured data abstraction form ensures consistency across reviewers. Elements to include:

• Patient demographics
• Clinical history and diagnosis
• Laboratory or imaging results
• Treatment regimens and changes
• Adverse events or hospitalizations
• Follow-up outcomes

Tools may be paper-based or electronic (eCRFs), ideally validated through a CSV validation protocol.

Step 5: Select and Train Reviewers

Reviewers should be trained in:

• Medical terminology and documentation practices
• Data abstraction guidelines
• Use of the abstraction tool or EDC system
• Maintaining data privacy and security

Conduct inter-rater reliability testing to ensure consistency, and keep training logs as per GMP documentation standards.

Step 6: Source and Prepare Medical Records

Identify the source sites (e.g., hospitals, clinics) and ensure:

• Access permissions are granted
• Systems are compatible with your data tools
• Medical records are complete and well-documented
• Data fields of interest are present and retrievable

Maintain a source data inventory and document missing or unusable records appropriately.

Step 7: Perform Data Abstraction and Entry

Key practices include:

• Double data entry or verification by a second reviewer
• Query resolution workflows for ambiguous entries
• Regular data reconciliation reports
• Audit trail creation for all entries and modifications

Apply edit checks to flag inconsistencies in real time using electronic platforms referenced on StabilityStudies.in.

Step 8: Data Analysis and Interpretation

Use descriptive and inferential statistics to evaluate:

• Baseline characteristics
• Frequency of outcomes or events
• Comparative analysis between groups (e.g., treated vs untreated)
• Subgroup analyses by age, comorbidities, etc.

Include methods to handle missing data, such as imputation or sensitivity analysis.

Step 9: Reporting and Publication

Prepare a comprehensive report including:

• Study design and methodology
• Descriptive and outcome data
• Limitations (e.g., missing data, confounding)
• Implications for practice, policy, or future research

Ensure that results comply with STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for transparency.

Step 10: Regulatory and Legal Considerations

Ensure long-term compliance with:

• HIPAA, GDPR, and other privacy laws
• Record retention policies
• De-identification or coding procedures
• Contracts with data providers (Data Use Agreements)

Conduct audits using checklists aligned with the SOP compliance pharma and maintain documentation for inspections.

Conclusion:

Planning a retrospective chart review study involves detailed protocol development, ethical compliance, robust data abstraction practices, and clear reporting strategies. By approaching these studies with precision and structure, pharma professionals can unlock powerful real-world insights that inform clinical decisions, policy changes, and regulatory filings. With the right tools and governance, chart reviews become more than a historical look—they become a strategic RWE asset.